Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Natera Inc    NTRA

NATERA INC (NTRA)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 07/17 07:36:58 pm
22.895 USD   +0.59%
07/12NATERA : Announces Pricing of Follow-On Offering
PR
07/10NATERA : Launches Proposed Follow-On Offering
PR
06/28NATERA,INC. (NA : NTRA) Files An 8-K Regulation FD Disclosure
AQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
20.58(c) 21.87(c) 21.59(c) 22.76(c) 22.82 Last
1 675 113 4 584 659 558 078 492 919 301 883 Volume
-2.19% +6.27% -1.28% +5.42% +0.26% Change
More quotes
Financials (USD)
Sales 2018 259 M
EBIT 2018 -108 M
Net income 2018 -118 M
Debt 2018 25,5 M
Yield 2018 -
Sales 2019 313 M
EBIT 2019 -59,7 M
Net income 2019 -71,5 M
Finance 2019 1,19 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 4,65x
EV / Sales2019 3,76x
Capitalization 1 177 M
More Financials
Company
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services.It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception,... 
More about the company
Surperformance© ratings of Natera Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on NATERA INC
07/13NATERA, INC. : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
07/12NATERA : Announces Pricing of Follow-On Offering
PR
07/10NATERA : Launches Proposed Follow-On Offering
PR
07/05NATERA : Develops Powerful Kidney Transplant Rejection Biomarker
AQ
06/28NATERA : Develops Powerful Kidney Transplant Rejection Biomarker
AQ
06/28NATERA,INC. (NASDAQ : NTRA) Files An 8-K Regulation FD Disclosure
AQ
06/27NATERA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
06/23NATERA : Develops Powerful Kidney Transplant Rejection Biomarker
AQ
06/21NATERA : To Host Investor Conference Call to Discuss Strategic Roadmap in Organ ..
PR
06/21NATERA : Develops Powerful Kidney Transplant Rejection Biomarker
PR
More news
Sector news : Diagnostic & Testing Substances
07/11Brazil prosecutors allege jailed GE executive helped company partake in medic..
RE
07/11MEDTRONIC : Gets FDA Approval for Less-Invasive Heart Pump Implant Procedure
DJ
07/09BECTON DICKINSON AND : Completes Acquisition of TVA Medical
DJ
06/29ESSILOR INTERNATIONAL : Luxottica, Essilor extend deadline for merger pending Ch..
RE
06/22LUXOTTICA : Italy's Luxottica buys sun lens maker Barberini for 140 million euro..
RE
More sector news : Diagnostic & Testing Substances
Latest Tweets
07/15Natera $NTRA & Foundation Medicine $FMI Head-To-Head Analysis  
07/12Natera $NTRA Trading 6% Higher  
07/12$NTRA: Natera prices 4.5M share offering at $20/share  
07/12DYNAMO GAPS UP: $NTRA - NATERA via ?  
07/12$NTRA (+3.0% pre) Natera Prices 4.5M Common Stock Offering at $20/Share - SI .. 
More tweets
Qtime:36
News from SeekingAlpha
07/12Natera announces pricing of follow-on offering, shares up 4.7% premarket 
07/10Natera launches stock offering; shares down 5% after hours 
06/29NATERA : A Quick Look At A Growing Testing Concern 
06/28Natera (NTRA) Kidney Transplant and Breast Cancer Program Update - Slideshow 
06/23STOCKS TO WATCH : More Trade Tiffs And Stress Tests 
Chart NATERA INC
Duration : Period :
Natera Inc Technical Analysis Chart | NTRA | US6323071042 | 4-Traders
Technical analysis trends NATERA INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 19,8 $
Spread / Average Target -13%
EPS Revisions
Managers
NameTitle
Matthew Rabinowitz Chairman, President & Chief Executive Officer
Stephen Chapman Chief Operating Officer
Michael Brophy Chief Financial Officer
Jonathan Sheena Director & Chief Technology Officer
Cheng-Ho Lin Chief Scientific Officer-Oncology
Sector and Competitors
1st jan.Capitalization (M$)
NATERA INC153.17%1 177
BIOMÉRIEUX3.49%10 649
DIASORIN SPA32.30%6 384
AUTOBIO DIAGNOSTICS CO LTD55.60%5 206
MACCURA BIOTECHNOLOGY CO LTD--.--%2 324
SIEGFRIED HOLDING AG26.85%1 741